Menu
 
Research menu
Jump to menu

Publications:  Dr Daniel Hart

Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola Ettingshausen C, Hart DP, Jiménez Yuste V et al.(2019). Common themes and challenges in hemophilia care: a multinational perspective. Hematology vol. 24, (1) 39-48.
10.1080/10245332.2018.1505225
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54940
Hart DP, Uzun N, Skelton S, Kakoschke A, Househam J, Moss DS, Shepherd AJ(2019). Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica vol. 104, (3) 599-608.
10.3324/haematol.2018.195669
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54937
Scott MJ, Xiang H, Hart DP, Palmer B, Collins PW, Stephensen D, Sima CS, Hay CRM(2019). Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia vol. 25, (2) 205-212.
10.1111/hae.13616
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54939
Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP et al.(2018). Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. J Thromb Haemost vol. 16, (11) 2196-2207.
10.1111/jth.14292
Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE et al.(2018). Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost vol. 2, (3) 535-548.
10.1002/rth2.12106
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55606
Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP et al.(2018). Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise. Haemophilia vol. 24, (4) 611-618.
10.1111/hae.13469
Batty P, Hart DP, Platton S(2018). Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A. Int J Lab Hematol
10.1111/ijlh.12862
Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, Hall G, Riddell A et al.(2018). Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia vol. 24, (3) 344-347.
10.1111/hae.13495
Dargaud Y, Delavenne X, Hart DP, Meunier S, Mismetti P(2018). Individualized PK-based prophylaxis in severe haemophilia. Haemophilia vol. 24 Suppl 2, 3-17.
10.1111/hae.13397
Collins P, Chalmers E, Alamelu J, Hay C, Liesner R, Makris M, Mathias M, Payne J et al.(2017). First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. Haemophilia vol. 23, (5) 654-659.
10.1111/hae.13264
Batty P, Austin SK, Khair K, Millar CM, Palmer B, Rangarajan S, Stümpel J-P, Thanigaikumar M et al.(2017). Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. Br J Haematol vol. 176, (5) 796-804.
10.1111/bjh.14543
Sivapalaratnam S, Westbury SK, Stephens JC, Greene D, Downes K, Kelly AM, Lentaigne C, Astle WJ et al.(2017). Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood vol. 129, (4) 520-524.
10.1182/blood-2016-08-732248
van Os SB, Troop NA, Sullivan KR, Hart DP(2017). Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients. PLoS One vol. 12, (1)
10.1371/journal.pone.0169880
Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D et al.(2017). The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany. Eur J Haematol vol. 98 Suppl 85, 1-15.
10.1111/ejh.12828
Maposa W, Bowles L, Fenton R, Foley C, Hart DP, Morris A, Pasi J, Patel V et al.(2016). Link nurse teaching day to bring haemophilia to ward nurses. HAEMOPHILIA vol. 22, 29-29.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15582
Stephensen D, Patel V, Hart D, Bowles L, Elliot K, Evans G, Pas J (2016). Monitoring joint range of motion in adults with severe haemophilia - evaluation of the haemophilia joint health score criteria. vol. 22, pp. 103-103.
Astermark J, Hart D, Lobet S, Blatný J, d'Oiron R, Kenet G, Dolan G, Libotte V et al.(2016). Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015. Eur J Haematol vol. 97 Suppl 84, 3-23.
10.1111/ejh.12761
Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M et al.(2016). The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands. Eur J Haematol vol. 97 Suppl 83, 3-18.
10.1111/ejh.12760
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15480
Simeoni I, Stephens JC, Hu F, Deevi SVV, Megy K, Bariana TK, Lentaigne C, Schulman S et al.(2016). A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood vol. 127, (23) 2791-2803.
10.1182/blood-2015-12-688267
Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D et al.(2016). A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. J Thromb Haemost vol. 14, (4) 757-764.
10.1111/jth.13253
van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Hart DP, Hamulyak K, Klamroth R, Meijer K et al.(2016). The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thromb Haemost vol. 115, (3) 543-550.
10.1160/TH15-03-0212
Berntorp E, Hart DP, Mancuso ME, D'Oiron R, Perry D (2016). The First Team Haemophilia Education (THE) Meeting: Highlights from an Educational Event Dedicated to Multidisciplinary Treatment Teams. HAEMOPHILIA. vol. 22, 101-101.
Stephensen D, Patel V, Elliot K, Bowles L, Hart DP, Pasi J(2016). The Relationship Between Clinical Joint Health and Functional Ability in Adult Men with Haemophilia. HAEMOPHILIA vol. 22, 51-51.
Badle S, Van Os S, Batty P, Pink R, Mangles S, Chowdary P, Collins P, Dolan G et al. (2016). UK-PK a Prospective National Study to Capture Patient Reported Outcome Measures Following a Pharmacokinetic (PK) Focused Educational Package in Patients with Severe Haemophilia A. HAEMOPHILIA. vol. 22, 26-26.
Shepherd A, Skelton S, Moss D, Hart D (2015). Modification of Predicted Inhibitor Risk in Non-Severe Hemophilia-a By in silico Analysis of Human Proteome Homology with Wild-Type, FVIII-Derived Peptides. BLOOD. vol. 126,
Batty P, Moore GW, Platton S, Maloney JC, Palmer B, Bowles L, Pasi KJ, Rangarajan S et al.(2015). Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost vol. 114, (4) 804-811.
10.1160/TH14-12-1062
Batty P, Hart DP(2015). Computational prediction of phenotype in haemophilia A. Haemophilia vol. 21, (5) 659-661.
10.1111/hae.12694
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A et al.(2015). Inhibitor development and mortality in non-severe hemophilia A. J Thromb Haemost vol. 13, (7) 1217-1225.
10.1111/jth.12990
van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K et al.(2015). Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost vol. 114, (1) 46-55.
10.1160/TH14-11-0940
Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK(2015). Ongoing risk of thrombosis with factor XI concentrate: 5years experience in two centres. HAEMOPHILIA vol. 21, (4) 490-495.
10.1111/hae.12682
Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK(2015). Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia vol. 21, (4) 490-495.
10.1111/hae.12682
Hay CRM, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M et al.(2015). The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia vol. 21, (2) 219-226.
10.1111/hae.12563
Shepherd AJ, Skelton S, Sansom CE, Gomez K, Moss DS, Hart DP(2015). A large-scale computational study of inhibitor risk in non-severe haemophilia A. Br J Haematol vol. 168, (3) 413-420.
10.1111/bjh.13131
Batty P, Palmer B, Chalmers E, Hay CRM, Liesner R, Rangarajan S, Talks K, Williams M et al.(2015). A national survey of immunosuppression strategies for acquired haemophilia A. Haemophilia vol. 21, (1) e73-e76.
10.1111/hae.12547
Khair K, Batty P, Riat R, Bowles L, Burgess C, Chen Y-H, Hart D, Platton S et al.(2015). Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience. Haemophilia vol. 21, (1) e44-e50.
10.1111/hae.12497
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6653
Collins PW, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M et al.(2014). Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood vol. 124, (23) 3389-3397.
10.1182/blood-2014-07-580498
Batty P, Chen Y-H, Bowles L, Hart DP, Platton S, Pasi KJ(2014). Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience. Haemophilia vol. 20, (6) 846-853.
10.1111/hae.12496
Batty P, Platton S, Bowles L, Pasi KJ, Hart DP(2014). Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. Br J Haematol vol. 166, (6) 953-956.
10.1111/bjh.12923
Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ(2014). Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): A single centre experience. Haemophilia
10.1111/hae.12496
Eckhardt CL, Loomans JI, Velzen ASV, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH et al.(2014). Clinical presentation of inhibitor development in non-severe hemophilia A: half of patients have high titer inhibitors and present with bleeding complications. HAEMOPHILIA vol. 20, 55-55.
Van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH et al.(2014). Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis. HAEMOPHILIA vol. 20, 49-49.
Kint M, Batty P, Peters M, Hart D(2014). National survey of online educational resource use: a UK hemophilia treaters' perspective. HAEMOPHILIA vol. 20, 35-35.
Loomans JI, Van Velzen AS, Eckhardt CL, Peters M, Astermark J, Brons PP, Carcao MD, Castaman G et al.(2014). Prediction of DDAVP response in 850 non-severe hemophilia A patients. HAEMOPHILIA vol. 20, 55-55.
Kint M, Batty P, Peters M, Robinson G, Hart D(2014). Survey of use of online educational resources: a UK hemophilia patients' and family members' perspective. HAEMOPHILIA vol. 20, 35-35.
Batty P, Rangarajan S, Austin S, Khair K, Millar C, Stuempel J-P, Thanigaikumar M, Yee TT et al.(2014). Uptake and timing of inhibitor screening in non-severe hemophilia A: results of a pan-London evaluation. HAEMOPHILIA vol. 20, 48-48.
Loomans JI, Van Velzen AS, Eckhardt CL, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH et al.(2014). Von Willebrand Factor antigen and age explain variation in baseline FVIII:C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser). HAEMOPHILIA vol. 20, 56-56.
Kint M, Batty P, Peters M, Hart D(2014). Wikipedia dominance in simulated online searching for hemophilia-specific patient information. HAEMOPHILIA vol. 20, 178-178.
Hart DP(2014). Computational modelling and inhibitor risk: predicting the future?. Haemophilia vol. 20, (2) 155-157.
10.1111/hae.12332
Batty P, Collins PW, Chalmers E, Hay CR, Liesner R, Palmer B, Rangarajan S, Talks K et al.(2014). A UKHCDO National Survey of the management of acquired haemophilia A. HAEMOPHILIA vol. 20, 31-31.
Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S(2014). The first recombinant FVIII produced in human cells--an update on its clinical development programme. Haemophilia vol. 20 Suppl 1, 1-9.
10.1111/hae.12322
Hart DP, Skelton S, Moss DS, Gomez K, Sansom C, Shepherd A(2013). Novel MHC peptide-T cell receptor interfaces are necessary for inhibitor formation in mild/moderate haemophilia a secondary to mis-sense mutation genotypes. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 8-8.
Hay CRM, Collins P, Palmer B, Liesner R, Chalmers E, Hart D, Rangarajan S, Ragarajan S et al.(2013). The incidence of factor VIII inhibitors in severe haemophilia a following a major product switch in the UK: a prospective controlled study in 1214 previously treated patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 9-9.
Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N et al.(2013). Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. BLOOD vol. 122, (11) 1954-1962.
10.1182/blood-2013-02-483263
Collins PW, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, Talks K, Williams M et al.(2013). Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. BRITISH JOURNAL OF HAEMATOLOGY vol. 162, (6) 758-773.
10.1111/bjh.12463
Platton SJ, Batty P, Bowles L, Pasi J, Hart DP(2013). Heat treatment and immunological testing substantially improves the detection of factor VIII antibodies in acquired haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 670-670.
Batty P, Moore GW, Platton SJ, Maloney JC, Bowles L, Pasi J, Rangarajan S, Hart DP(2013). Immunological detection of factor VIII antibodies in congenital and acquired haemophilia A. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 11, 930-930.
Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD et al.(2013). The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost vol. 11, (2) 307-314.
10.1111/jth.12078
Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR(2013). Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). BRITISH JOURNAL OF HAEMATOLOGY vol. 160, (2) 153-170.
10.1111/bjh.12091
Kint M, Hart DP(2012). Should clinicians edit Wikipedia to engage a wider world web?. BMJ vol. 345,
10.1136/bmj.e4275
Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP(2012). Access to primary dental care for patients with inherited bleeding disorders. Haemophilia vol. 18, (4) 510-515.
10.1111/j.1365-2516.2011.02716.x
Islam A, Doly E, Yunnus A, Kabir A, Islam N, Mathias M, Mclaughlin P, Hubert N et al.(2012). Hemophilia 2012-London-Moscow-Dhaka: A Comparative, Observational Study of the Musculoskeletal Impact of Severe Hemophilia in Twenty Boys in Each City. HAEMOPHILIA vol. 18, 193-193.
Osias A, Sager R, Danga E, Morris A, Forsyth K, Adetona T, Williams H, Townsend P et al.(2012). Implementation of an online home treatment record-keeping system (Haemtrack) in a large London comprehensive care centre. HAEMOPHILIA vol. 18, 59-59.
Skelton S, Moss D, Sansom C, Gomez K, Shepherd A, Hart D(2012). Novel MHC-PEPTIDE-T cell receptor interfaces are necessary for inhibitor formation in mild/moderate hemophilia A secondary to missense mutation genotypes. HAEMOPHILIA vol. 18, 86-86.
Kalsi H, Nanayakkara L, Danga E, Bowles L, Jones J, Pasi J, Hart D(2012). Regular primary dental care access for patients with inherited bleeding disorders: The barriers and solutions. HAEMOPHILIA vol. 18, 48-48.
HART DP, Batty P, Platton S(2012). Treatment of Hemophilia A in countries with limited resources. Blood vol. 119, 4108-4114.
10.1182/blood-2012-01-394411
Bowles L, Morris A, Forsyth K, Sager R, Osias A, Danga E, Townsend P, Murphy U et al. (2012). Computerised patient records enhance communication, audit potential and patient safety in a large haemophilia comprehensive care centre. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 39-39.
Skelton S, Moss D, Sansom C, Gomez K, Shepherd AJ, Hart DP (2012). Novel MHC-peptide-T cell receptor interfaces are necessary for inhibitor formation in mild/moderate haemophilia A secondary to missense mutation genotypes. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 10-10.
Mcloughlin TF, Chan MV, Warner TD, Hart DP (2012). Validation of a novel, high-throughput platelet aggregation technique. HAEMOPHILIA. vol. 18, 18-19.
Davenport R, Manson J, De'Ath H, Platton S, Coates A, Allard S, Hart D, Pearse R et al.(2011). Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med vol. 39, (12) 2652-2658.
10.1097/CCM.0b013e3182281af5
HART D, Cooper N, Bates I, Cotter FE(2011). The importance of developing world haematology. British Journal of Haematology vol. 6, (154)
Davenport R, Rourke C, Manson J, De'Ath H, Platton S, Coates A, Hart D, Pearse P et al.(2011). Activated protein C is a principle mediator of acute traumatic coagulopathy. J THROMB HAEMOST vol. 9, 51-52.
Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, Hunt B, Benjamin S et al.(2011). Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol vol. 153, (4) 515-519.
10.1111/j.1365-2141.2011.08636.x
Davenport R, Manson J, De'Ath H, Platton S, Coates A, Allard S, Hart D, Pearse R et al. (2011). Point of care diagnostics for the rapid identification of acute traumatic coagulopathy and prediction of massive trauma haemorrhage. BRITISH JOURNAL OF SURGERY. vol. 98, 7-7.
Uprichard J, Mills S, MacCallum PK, Cheshire C, Hart DP (2011). The use of an electronic patient record to improve patient safety for anticoagulation. BRITISH JOURNAL OF HAEMATOLOGY. vol. 153, 81-82.
Perro M, Tsang J, Xue S-A, Escors D, Cesco-Gaspere M, Pospori C, Gao L, Hart D et al.(2010). Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther vol. 17, (6) 721-732.
10.1038/gt.2010.4
Xue S-A, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss R-H, Morris E et al.(2010). Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica vol. 95, (1) 126-134.
10.3324/haematol.2009.006486
Hart DP, Xue S-A, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N et al.(2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther vol. 15, (8) 625-631.
10.1038/sj.gt.3303078
Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue S-A, Holler A, King J, Wright G et al.(2008). WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis vol. 40, (1) 113-116.
10.1016/j.bcmd.2007.06.018
Thomas S, Xue S-A, Cesco-Gaspere M, San José E, Hart DP, Wong V, Debets R, Alarcon B et al.(2007). Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol vol. 179, (9) 5803-5810.
10.4049/jimmunol.179.9.5803
Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue S-A, Holler A, Wright G, Perro M et al.(2007). Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther vol. 15, (10) 1744-1750.
10.1038/sj.mt.6300216
Hart DP, Peggs KS(2007). Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies. Clin Pharmacol Ther vol. 82, (3) 325-329.
10.1038/sj.clpt.6100283
Thomas S, Hart DP, Xue S-A, Cesco-Gaspere M, Stauss HJ(2007). T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther vol. 7, (8) 1207-1218.
10.1517/14712598.7.8.1207
Briggs C, Hart D, Kunka S, Oguni S, Machin SJ(2006). Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med vol. 16, (2) 101-109.
10.1111/j.1365-3148.2006.00654.x
Morris E, Hart D, Gao L, Tsallios A, Xue S-A, Stauss H(2006). Generation of tumor-specific T-cell therapies. Blood Rev vol. 20, (2) 61-69.
10.1016/j.blre.2005.05.001
Xue S-A, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B et al.(2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood vol. 106, (9) 3062-3067.
10.1182/blood-2005-01-0146
Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S(2005). The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant vol. 35, (11) 1065-1069.
10.1038/sj.bmt.1704959
Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ et al.(2005). Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol vol. 128, (6) 824-829.
10.1111/j.1365-2141.2005.05388.x
Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F et al.(2004). WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis vol. 33, (3) 288-290.
10.1016/j.bcmd.2004.08.018
Briggs C, Kunka S, Hart D, Oguni S, Machin SJ(2004). Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol vol. 126, (1) 93-99.
10.1111/j.1365-2141.2004.04987.x
Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F et al.(2004). Use of the allogeneic TCR repertoire to enhance anti-tumor immunity. J Biol Regul Homeost Agents vol. 18, (2) 131-133.
Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, Goldstone AH, Linch DC et al.(2004). Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood vol. 103, (4) 1548-1556.
10.1182/blood-2003-05-1513
Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, Goulden N, Oakhill A et al.(2001). The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol vol. 113, (1) 58-64.
10.1046/j.1365-2141.2001.02699.x
Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C(1993). Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer vol. 55, (3) 498-505.
10.1002/ijc.2910550329
Return to top